Please use this identifier to cite or link to this item:
|Title:||A clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit.|
|Authors:||Stephens, Dianne P|
Thomas, Jane H
Collins, Sarah J
Goldrick, Paul B
|Affiliation:||Royal Darwin Hospital, Darwin, NT, Australia. firstname.lastname@example.org.|
|Citation:||Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine 2007-06; 9(2): 148-50|
|Abstract:||To formally document the effectiveness of tegaserod as a prokinetic agent in intensive care patients. The audit was designed in consultation with the Northern Territory Drug and Therapeutics Committee. Tegaserod was added to the feeding protocol and prokinetic algorithm in the ICU, and a prospective audit was performed of patients receiving the medication between May and September 2006. Over the 5-month period, 40 patients received tegaserod after failing to respond to two doses of metoclopramide. Median daily volume of gastric aspirate was reduced from 1220mL in the 24 hours before tegaserod to 887.5mL in the first 24 hours after its introduction, and to 280mL in the second 24 hours (P=0.01 and P<0.001, respectively). Tegaserod was an effective prokinetic agent in 85% (34) patients. Attributable diarrhoea occurred in 13% (5) patients, but did not require intervention. Tegaserod is an effective alternative prokinetic agent for ICU patients with a safer side-effect profile. We believe it warrants further investigation.|
Intensive Care Units
Irritable Bowel Syndrome
Serotonin Receptor Agonists
|Appears in Collections:||NT Health digital library|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.